Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Pharmacokinetic characterization of antisense oligonucleotides (ASOs) in rodent and NHP studies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Pharmacokinetic characterization of antisense oligonucleotides (ASOs) in rodent and NHP studies

In Vivo Characterization of Antisense Oligonucleotides (ASOs)

CELL & GENE | RNA | BIOLOGICS

Executive Summary

Successful Investigational New Drug (IND) applications for antisense oligonucleotides (ASOs) depend on a comprehensive characterization of their in vivo behavior. A robust understanding of an ASO’s absorption, distribution, metabolism, and excretion (ADME) profile, derived from well-designed animal studies, is necessary to establish a clear therapeutic window. This page outlines the strategic approach to designing and executing IND-enabling biodistribution and pharmacokinetic (PK) studies for ASO candidates in rodent and non-human primate (NHP) models, aligning with an 18-24 month IND timeline.

What are the key design considerations for ASO biodistribution studies?
A successful study requires careful selection of species, dose levels, and collection time points. The study design must account for the unique disposition of ASOs, which often involves rapid clearance from plasma but prolonged retention in tissues like the liver and kidney. Protocols must balance the need for comprehensive tissue collection with the 3Rs principles of animal welfare.
Which species are most relevant for IND-enabling ASO programs?
Rodent models are typically used for initial screening and dose-range finding. For IND-enabling toxicology and disposition studies, non-human primates (NHPs) are frequently the most appropriate species. This is due to the high degree of sequence homology required for on-target pharmacodynamic activity and the need to assess potential effects in a translationally relevant system.
How is the disposition of ASOs in tissues evaluated?
An ASO’s biodistribution profile is built by analyzing drug concentrations in a panel of key organs collected at designated time points post-dose. This quantitative data on non-target tissue biodistribution reveals patterns of accumulation and retention. The findings are often supplemented with qualitative Histology techniques, such as in situ hybridization (ISH), to visualize cellular uptake and distribution within a tissue.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Defining Oligonucleotide Exposure and Disposition In Vivo

ASOs exhibit unique in vivo properties, characterized by high protein binding and active uptake into tissues. This leads to prolonged terminal half-lives in organs like the liver and kidney, even as plasma concentrations decline. A successful preclinical program depends on accurately modeling this behavior in relevant biological systems.

The goals of in vivo ASO characterization include defining:

  • Systemic Exposure: Determining Cmax, Tmax, and AUC from plasma concentration data.

  • Tissue Distribution: Assessing drug concentration in a comprehensive panel of tissues to understand accumulation and retention.

  • Metabolite Exposure: Characterizing the in vivo exposure of major chain-shortened metabolites, which may retain biological activity.

  • Elimination Pathways: Identifying the primary routes of clearance, which is predominantly renal.

Translational Study Design for IND-Enabling Programs

Designing an effective ASO disposition study requires a deep understanding of the intended clinical application and regulatory expectations. Our scientific team works directly with sponsors to develop protocols that generate clear, decision-driving data within our >100,000 sq ft GxP-compliant facility. This collaborative approach is central to our programs, which have achieved a 100% IND success rate since 2019. (The Franklin Biolabs brand launched in 2024).

The strategic value of robust in vivo characterization is well-established. For instance, identifying and confirming the functional activity of a novel splice variant in vivo was a necessary step in the development of a gene therapy, demonstrating that preclinical models must be capable of recapitulating complex biological mechanisms (PMID: 21628398). Similarly, foundational work to confirm the functional expression of therapeutic constructs is a prerequisite for advancing into complex in vivo studies, ensuring that the asset performs as designed before significant resource investment (PMID: 15452712). These principles guide our approach to ASO characterization, ensuring that exposure data is directly linked to a clear translational hypothesis.

Study Component Rodent Models NHP Models
Primary Use Case PK/PD screening, dose-range finding IND-enabling safety and disposition studies
Key Endpoints Plasma exposure, target organ concentration Systemic exposure, comprehensive tissue disposition
Study Complexity Shorter duration, targeted sample collection Longer duration, extensive sample matrices
Regulatory Weight Supporting Pivotal for IND submission

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Animal Welfare and GxP Compliance

All in vivo studies are conducted in strict compliance with GxP standards and executed within AAALAC-accredited, USDA-registered facilities. This infrastructure reflects our commitment to the highest ethical standards for animal care and use. We rigorously apply the 3Rs (Replacement, Reduction, and Refinement) principles to every study design, ensuring that data is maximized from the minimum number of animals required for statistical power.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities